Ovarian Cancer Clinical Trials in Fort Worth, Texas

10 studies are recruiting for ovarian cancer in Fort Worth, Texas right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC

   The goal of this clinical study is to learn more about the study drug, TUB-040, including its safety, tolerability, pharmacokinetics, and preliminary efficacy, and to determine the best dose of TUB-040 in participants with ovarian cancer or non-small cell lung cancer (NSCLC). The primary objectives…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Dallas Fort Worth, Fort Worth, Texas

   Locations

   21 in total

   Run by

   Gilead Sciences

   See if you can join NCT06303505 on ClinicalTrials.gov

2. A Clinical Trial of Raludotatug Deruxtecan (R-DXd) With or Without Bevacizumab in Participants With Ovarian Cancer Who Have Progressed During Treatment With PARP-inhibitors Treatment on First Line Maintenance (MK-5909-008/ENGOT-ov107/GOG-3142 / REJOICE-Ovarian05)

   Researchers are looking for new ways to treat advanced, high-grade ovarian cancer (OC). Advanced means the cancer has spread to other parts of the body (metastatic) and may not be removed with surgery. High-grade means the cancer cells grow and spread quickly. This trial includes types of OC that s…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   JPS Oncology and Infusion Center ( Site 0019), Fort Worth, Texas

   Locations

   6 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07743164 on ClinicalTrials.gov

3. A Study of Raludotatug Deruxtecan With or Without Bevacizumab as First-Line Maintenance Treatment in Non-HRD-Positive Advanced Ovarian Cancer (MK-5909-006, (ENGOT-ov102/GOG-3141/ REJOICE-Ovarian 04)

   Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: Maintenance treatment, which is used…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - DFW ( Site 8005), Fort Worth, Texas

   Locations

   11 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT07776691 on ClinicalTrials.gov

4. Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression

   The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Jps Health Network, Fort Worth, Texas

   Locations

   198 in total

   Run by

   Incyte Corporation

   See if you can join NCT07214779 on ClinicalTrials.gov

5. Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Start - Dfw, Fort Worth, Texas

   Locations

   26 in total

   Run by

   SystImmune Inc.

   See if you can join NCT06293898 on ClinicalTrials.gov

6. A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Platinum-sensitive Recurrent Ovarian Cancer (MK-2870-022/TroFuse-022/ENGOT-ov84/GOG-3103)

   The main goals of this study are to learn about the safety of sacituzumab tirumotecan with bevacizumab and if people tolerate it; and if people who take sacituzumab tirumotecan with or without bevacizumab live longer without the cancer getting worse than those who receive standard of care treatment.

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Texas Oncology - DFW ( Site 8001), Fort Worth, Texas

   Locations

   198 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06824467 on ClinicalTrials.gov

7. A Study to Assess Adverse Events and Change in Disease Activity of Multiple Treatment Combinations With Intravenous Mirvetuximab Soravtansine in Adult Participants With Ovarian Cancer

   Ovarian cancer is a lethal disease with an estimated 310,000 new cases and 200,000 deaths experienced worldwide in 2020. The purpose of this study is to assess the adverse events and change in disease activity of mirvetuximab soravtansine with carboplatin, or bevacizumab (Bev), or bev alone in part…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Texas Oncology - Fort Worth Cancer Center /ID# 277989, Fort Worth, Texas

   Locations

   86 in total

   Run by

   AbbVie

   See if you can join NCT07059845 on ClinicalTrials.gov

8. A Study of PHST001 in Advanced Solid Tumors

   This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with anticancer therapies (Phase 1b) in adult participants with advan…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   START Center for Cancer Research - Texas, Fort Worth, Texas

   Locations

   20 in total

   Run by

   Pheast Therapeutics

   See if you can join NCT06840886 on ClinicalTrials.gov

9. Phase 1, Safety and Tolerability Study of XmAb541 and XmAb808 in Advanced Solid Tumors

   The primary purpose of this study is to determine whether the combination of the investigational drug XmAb541 in combination with the investigational drug XmAb808 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of X…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Xencor Investigative Site, Fort Worth, Texas

   Locations

   4 in total

   Run by

   Xencor, Inc.

   See if you can join NCT07593092 on ClinicalTrials.gov

10. Dose Determining Study of EXS74539 (REC-4539) in Participants With Select Solid Tumors

    The primary purpose of this study is to determine the safety, tolerability, and maximum tolerated dose (MTD) of EXS74539 (REC-4539) in participants with select solid tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    START Dallas, Fort Worth, Texas

    Locations

    3 in total

    Run by

    Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

    See if you can join NCT07517198 on ClinicalTrials.gov